Project MK 3475 - 669 – A Phase III Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of…

Basic data

Acronym:
MK 3475 - 669
Title:
A Phase III Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Duration:
01/04/2018 to 30/06/2021
Abstract / short description:
The efficacy and safety of combination therapy of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and EXTREME regimen is being investigated as a first line treatment for participants with recurrent or metastatic (R/M) head and neck squamous cell cancers (HNSCC) in this randomized, open-label, Phase 3 study.
Keywords:
Pembrolizumab
Hals-Nasen-Ohrenheilkunde
Head &Neck Cancer
Otolaryngology
Oncology

Involved staff

Managers

Faculty of Medicine
University of Tübingen

Local organizational units

Department of Otolaryngology, Head and Neck Surgery; Polyclinic
Hospitals and clinical institutes
Faculty of Medicine

Funders

Haar, Bayern, Germany
Help

will be deleted permanently. This cannot be undone.